Trial Profile
A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of pertuzumab (rhuMab 2C4) in combination with gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Genentech
- 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00096993)
- 09 Nov 2009 Results have been presented in the Journal of Clinical Oncology.
- 01 Jul 2008 Results presented at the American Society of Clinical Oncology (ASCO) 2008.